{"slug":"guideline","tag":"guideline","variants":["guideline"],"description":"No description yet","count":2,"kinds":{"collection":1,"paper":1},"related":[{"slug":"late-effects","tag":"late-effects","shared":1},{"slug":"paediatric","tag":"paediatric","shared":1},{"slug":"precision","tag":"precision","shared":1},{"slug":"rejuvenation","tag":"rejuvenation","shared":1},{"slug":"survivorship","tag":"survivorship","shared":1}],"records":[{"id":"ighg","kind":"collection","name":"International Guideline Harmonization Group for late effects of childhood cancer","route":"/collections/ighg/","tldr":"Three countries wrote three different sets of follow-up rules for the same survivors, and the rules disagreed about who to screen, how and how often. Since 2010 this group has been settling those disagreements one organ at a time, in public, with the evidence graded and the disagreement named."},{"id":"paper-esmo-ctdna-assay-recommendations-ann-oncol-2022","kind":"paper","name":"ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group","route":"/key-papers/paper-esmo-ctdna-assay-recommendations-ann-oncol-2022/","tldr":"Europe's oncology society advised that blood tests for tumour DNA can guide targeted treatment in advanced cancer, that tissue is still preferred for many patients, and that residual disease tests after surgery were not yet ready for routine use."}]}